查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1500282

肺炎鏈球菌疫苗市場：按類型、適應症、年齡層、分佈分類 - 2024-2030 年全球預測

Pneumococcal Vaccine Market by Type (Conjugate Vaccines, Polysaccharide Vaccines), Indication (Bronchitis, Meningitis, Pneumonia), Age Group, Distribution - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年肺炎鏈球菌疫苗市場規模為107.3億美元，預計2024年將達115.6億美元，2030年將達183億美元，複合年成長率為7.92%。

肺炎鏈球菌疫苗旨在預防鏈球菌引起的感染疾病。這些感染疾病的範圍從耳朵和鼻竇感染疾病到肺炎、腦膜炎和血液感染疾病等嚴重。這種疫苗對於兒童、老年人和患有某些健康狀況且更容易感染這種疾病的人來說至關重要。隨著世界人口老化以及越來越多的人面臨慢性疾病的風險，肺炎球菌疾病的盛行率不斷增加，從而增加了對肺炎球菌疫苗的需求。政府和國際衛生組織對肺炎球菌疫苗的支持正在推動市場成長。這些疫苗通常被納入國家免疫計劃中，因為它們可以降低細菌感染疾病的發生率，尤其是兒童和老年人。人們對免疫重要性的認知不斷提高，加上公共衛生宣傳活動和教育計畫的加強，正在支持肺炎鏈球菌疫苗市場的成長。高開發成本和複雜的疫苗儲存和處理要求阻礙了市場成長。疫苗技術的改進以及針對不同菌株提供廣泛保護的結合疫苗的持續開發預計將為肺炎球菌疫苗市場創造機會。

主要市場統計
基準年[2023] 107.3億美元
預測年份 [2024] 115.6億美元
預測年份 [2030] 183億美元
複合年成長率（%） 7.92%

區域洞察

美國擁有發達的醫療保健系統，對疫苗接種方案（包括肺炎球菌疫苗接種，尤其是嬰幼兒和老年人）的認知度很高，並且是一個高度發展的新興市場。將免疫計畫納入公共衛生政策等政策舉措將進一步刺激疫苗接種率。在亞太地區，由於政府在經濟開拓、醫療基礎設施和疫苗接種方面的政策存在差異，各國的市場動態差異很大。日本、澳洲和韓國等國家由於有利的醫療保健政策和預防保健意識的提高，肺炎鏈球菌疫苗接種覆蓋率很高。另一方面，由於醫療基礎設施改善、中等收入群體增加以及政府推廣肺炎鏈球菌感染疫苗接種，印度、日本、中國等新興國家的疫苗接種率正在迅速上升。歐洲是肺炎球菌疫苗的強大市場，擁有全面的醫療保健系統和廣泛的疫苗接種覆蓋率。由於醫療保健能力不同以及政府對免疫計劃的支持程度不同，中東和非洲的疫苗普及參差不齊。與東歐國家相比，西歐國家的疫苗接種率普遍較高。同時，非洲和中東部分地區仍在繼續努力改善疫苗取得和疫苗接種率，這通常得到國際衛生組織的支持。

FPNV定位矩陣

FPNV 定位矩陣對於評估肺炎鏈球菌疫苗市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對肺炎鏈球菌疫苗市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對當前肺炎球菌疫苗市場地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肺炎鏈球菌感染的傳播
      • 加強有關肺炎鏈球菌疫苗接種的宣傳計劃
    • 抑制因素
      • 研發肺炎鏈球菌疫苗成本高昂
    • 機會
      • 推出新型肺炎鏈球菌疫苗，針對不同菌株提供更廣泛的保護
      • 完善低溫運輸網路，拓展新型配送體系發展
    • 任務
      • 疫苗生產臨床試驗處理緩慢
  • 市場區隔分析
    • 類型：增加使用產生強烈免疫反應（包括記憶反應）的結合疫苗
    • 分發：透過政府當局擴大肺炎球菌疫苗的供應，並提高高風險族群的疫苗接種率
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 肺炎鏈球菌疫苗市場：依類型

  • 結合疫苗
  • 多醣體疫苗

第7章 肺炎鏈球菌疫苗市場適應症

  • 支氣管炎
  • 腦膜炎
  • 肺炎
  • 敗血症

第8章肺炎鏈球菌疫苗市場：依年齡層別

  • 成人
  • 嬰幼兒

第9章 肺炎鏈球菌疫苗市場經銷商

  • 政府機關
  • 非政府組織

第10章美洲肺炎鏈球菌疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太肺炎鏈球菌疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲肺炎鏈球菌疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准默克公司的新型肺炎球菌疫苗提供廣泛保護
    • Vaxcyte 透過加強與 Lonza 在肺炎鏈球菌疫苗生產方面的合作來加強全球供應鏈
    • FDA核准輝瑞 Prevenar 20，這是預防肺炎鏈球菌感染的重大突破
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-43539E5D3200

[184 Pages Report] The Pneumococcal Vaccine Market size was estimated at USD 10.73 billion in 2023 and expected to reach USD 11.56 billion in 2024, at a CAGR 7.92% to reach USD 18.30 billion by 2030.

The pneumococcal vaccine is designed to protect against infections caused by the streptococcus pneumoniae bacteria. These infections range from ear and sinus infections to more severe illnesses, including pneumonia, meningitis, and bloodstream infections. The vaccine is essential for children, the elderly, and individuals with certain health conditions that make them more vulnerable to disease. With the increasing prevalence of pneumococcal diseases as global populations age and more individuals are at risk of chronic diseases, there is an increased need for pneumococcal vaccines. The availability of support from governments and international health organizations for pneumococcal vaccines is driving the market growth. These vaccines are often included in national immunization schedules to reduce the incidence of bacterial infections, especially in children and the elderly. Growing awareness about the importance of immunizations, bolstered by public health campaigns and education programs, supports the growth of the pneumococcal vaccine market. The high development cost and complex vaccine storage and handling requirements hamper the market growth. Rising improvements in vaccine technology and the development of conjugate vaccines that provide broader protection against various strains of bacteria are expected to create opportunities for the pneumococcal vaccine market.

KEY MARKET STATISTICS
Base Year [2023] USD 10.73 billion
Estimated Year [2024] USD 11.56 billion
Forecast Year [2030] USD 18.30 billion
CAGR (%) 7.92%

Regional Insights

America shows a highly developing pneumococcal vaccine market with well-structured healthcare systems and high awareness regarding vaccination protocols, including pneumococcal vaccination, especially for infants and the elderly segment of the population. Policy initiatives, including immunization programs integrated into public health policy, further stimulate vaccine coverage. In APAC, the market dynamics vary widely across countries due to differences in economic development, healthcare infrastructure, and government policies related to vaccinations. Countries such as Japan, Australia, and South Korea exhibit higher adoption rates for pneumococcal vaccines, driven by favorable healthcare policies and a rising awareness of preventive healthcare. Meanwhile, emerging economies such as India, Japan, and China are experiencing rapid growth in vaccine uptake due to improving healthcare infrastructure, increasing middle-class populations, and government immunization drives against pneumococcal diseases. Europe is a strong market for pneumococcal vaccines, supported by comprehensive healthcare systems and wide vaccine coverage. The Middle East and Africa show varied vaccine adoption rates due to contrasting healthcare capabilities and varying levels of government support for immunization programs. Western European countries generally report higher vaccination rates compared to Eastern European nations. Meanwhile, in Africa and some parts of the Middle East, efforts are ongoing to enhance vaccine access and inoculation rates, often supported by international health organizations.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Pneumococcal Vaccine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of pneumococcal diseases
      • Rising awareness programs regarding the use of pneumococcal vaccination
    • Market Restraints
      • High cost associated with the development of pneumococcal vaccines
    • Market Opportunities
      • Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
      • Improving cold chain networks and growing development of novel delivery systems
    • Market Challenges
      • Slow processing of clinical trials for the production of vaccine
  • Market Segmentation Analysis
    • Type: Growing usage of conjugate vaccines to produce a strong immune response that includes a memory response
    • Distribution: Growing availability of pneumococcal vaccine through government authorities for enhancing vaccination coverage among at-risk populations
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pneumococcal Vaccine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pneumococcal Vaccine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Approves Merck's New Pneumococcal Vaccine Targeting Broad Protection

The U.S. Food and Drug Administration (FDA) approved Merck's innovative 21-valent pneumococcal conjugate pneumococcal vaccine, designed to offer protection against a comprehensive range of pneumococcal disease strains. This approval underscores a significant advancement in public health, promising enhanced protection for individuals, especially vulnerable populations such as older people and those with compromised immune systems. Merck's vaccine, which has demonstrated efficacy in preventing infections caused by numerous strains of pneumococcal bacteria, aims to reduce the incidence and severity of pneumococcal diseases such as pneumonia, meningitis, and bloodstream infections. [Published On: 2023-12-20]

Vaxcyte Bolsters Global Supply Chain with Enhanced Lonza Collaboration for Pneumococcal Vaccine Production

Vaxcyte, Inc. is expanding its collaboration with Lonza, a key global player in the pharmaceutical and biotech manufacturing sector, to elevate the production of VAX-24, its 24-valent pneumococcal conjugate vaccine candidate. This strategic partnership aims to reinforce Vaxcyte's manufacturing capabilities to meet global commercial demands, anticipating the transition into the pivotal Phase 3 vaccine trial. This collaboration underscores both companies' commitment to addressing the wide-ranging pneumococcal disease threat with a next-generation vaccine that could significantly impact public health worldwide. [Published On: 2023-10-16]

FDA Approves Pfizer's Prevnar 20 a Significant Advancement in Pneumococcal Disease Prevention

The U.S. Food and Drug Administration (FDA) has recently approved Prevnar 20, a novel 20-valent pneumococcal conjugate vaccine developed by Pfizer. This approval marks a significant milestone in preventing pneumococcal diseases, as Prevnar 20 is designed to protect against twenty pneumococcal serotypes responsible for most pneumococcal disease cases and pneumonia. The vaccine is authorized for use in adults aged 18 years and older, offering enhanced coverage and aiming to improve public health outcomes by reducing the incidences of these severe infections. This development is particularly timely, considering the substantial health burden pneumococcal diseases place on individuals and healthcare systems globally. [Published On: 2023-04-27]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pneumococcal Vaccine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Pneumococcal Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Biological E. Limited, Biovac, CSL Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Incepta Pharmaceuticals Ltd., Lonza AG, Merck & Co., Inc., Panacea Biotec Limited, Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pneumococcal Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Conjugate Vaccines
    • Polysaccharide Vaccines
  • Indication
    • Bronchitis
    • Meningitis
    • Pneumonia
    • Sepsis
  • Age Group
    • Adults
    • Infants & Young Children
  • Distribution
    • Government Authorities
    • Non-Governmental Organizations
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pneumococcal diseases
      • 5.1.1.2. Rising awareness programs regarding the use of pneumococcal vaccination
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the development of pneumococcal vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
      • 5.1.3.2. Improving cold chain networks and growing development of novel delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Slow processing of clinical trials for the production of vaccine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing usage of conjugate vaccines to produce a strong immune response that includes a memory response
    • 5.2.2. Distribution: Growing availability of pneumococcal vaccine through government authorities for enhancing vaccination coverage among at-risk populations
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Pneumococcal Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Conjugate Vaccines
  • 6.3. Polysaccharide Vaccines

7. Pneumococcal Vaccine Market, by Indication

  • 7.1. Introduction
  • 7.2. Bronchitis
  • 7.3. Meningitis
  • 7.4. Pneumonia
  • 7.5. Sepsis

8. Pneumococcal Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Infants & Young Children

9. Pneumococcal Vaccine Market, by Distribution

  • 9.1. Introduction
  • 9.2. Government Authorities
  • 9.3. Non-Governmental Organizations

10. Americas Pneumococcal Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumococcal Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumococcal Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Merck's New Pneumococcal Vaccine Targeting Broad Protection
    • 13.3.2. Vaxcyte Bolsters Global Supply Chain with Enhanced Lonza Collaboration for Pneumococcal Vaccine Production
    • 13.3.3. FDA Approves Pfizer's Prevnar 20 a Significant Advancement in Pneumococcal Disease Prevention
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PNEUMOCOCCAL VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. PNEUMOCOCCAL VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PNEUMOCOCCAL VACCINE MARKET DYNAMICS
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY BRONCHITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY MENINGITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PNEUMONIA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY SEPSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY SEPSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INFANTS & YOUNG CHILDREN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INFANTS & YOUNG CHILDREN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GOVERNMENT AUTHORITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GOVERNMENT AUTHORITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 61. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 69. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 77. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 105. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 113. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 121. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 129. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 137. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 153. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 169. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 177. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 185. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 203. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 211. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 219. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 227. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 235. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 243. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 251. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 267. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 275. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 283. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 291. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 299. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 323. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 331. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 339. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 347. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 348. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 349. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 350. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 351. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
  • TABLE 352. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 356. UNI